Management of cardiovascular disease in Turner syndrome.
As a result of the multitude of potential comorbidities, patients with Turner syndrome require lifelong cardiac care. This review summarizes the current state of knowledge of the cardiovascular pathology present in patients with Turner syndrome and outlines recommendations for cardiac care from birth through to adulthood.
Thomas
Joshua
J
University of Utah, Salt Lake City, UT 84105, USA.
Yetman
Anji T
AT
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000453:epidemiology* / Q000235:genetics; D015897:Comorbidity; D005260:Female; D006330:Heart Defects, Congenital / Q000188:drug therapy / Q000453:epidemiology / Q000235:genetics; D020249:Hormone Replacement Therapy; D019382:Human Growth Hormone / Q000627:therapeutic use; D006801:Humans; D017410:Practice Guidelines as Topic; D014424:Turner Syndrome / Q000188:drug therapy / Q000453:epidemiology* / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D019382:Human Growth Hormone